Gastric Motility Disorder Drug Market Size, Share, and Trends 2026 to 2035

Gastric Motility Disorder Drug Market (By Type: Velusetrag, Ipamorelin, TD-8954, Others; By Application: Hospital, Clinic, Home Use) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2026 to 2035

Last Updated : 24 Dec 2025  |  Report Code : 2688  |  Category : Healthcare   |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gastric Motility Disorder Drug Market 

5.1. COVID-19 Landscape: Gastric Motility Disorder Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gastric Motility Disorder Drug Market, By Type

8.1. Gastric Motility Disorder Drug Market Revenue and Volume, by Type

8.1.1. Velusetrag

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Ipamorelin

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. TD-8954

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Gastric Motility Disorder Drug Market, By Application

9.1. Gastric Motility Disorder Drug Market Revenue and Volume, by Application

9.1.1. Hospital

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Clinic

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Home Use

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Gastric Motility Disorder Drug Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Type

10.1.2. Market Revenue and Volume Forecast, by Application

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Type

10.1.3.2. Market Revenue and Volume Forecast, by Application

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Type

10.1.4.2. Market Revenue and Volume Forecast, by Application

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Type

10.2.2. Market Revenue and Volume Forecast, by Application

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Type

10.2.3.2. Market Revenue and Volume Forecast, by Application

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Type

10.2.4.2. Market Revenue and Volume Forecast, by Application

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Type

10.2.5.2. Market Revenue and Volume Forecast, by Application

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Type

10.2.6.2. Market Revenue and Volume Forecast, by Application

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Type

10.3.2. Market Revenue and Volume Forecast, by Application

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Type

10.3.3.2. Market Revenue and Volume Forecast, by Application

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Type

10.3.4.2. Market Revenue and Volume Forecast, by Application

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Type

10.3.5.2. Market Revenue and Volume Forecast, by Application

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Type

10.3.6.2. Market Revenue and Volume Forecast, by Application

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Type

10.4.2. Market Revenue and Volume Forecast, by Application

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Type

10.4.3.2. Market Revenue and Volume Forecast, by Application

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Type

10.4.4.2. Market Revenue and Volume Forecast, by Application

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Type

10.4.5.2. Market Revenue and Volume Forecast, by Application

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Type

10.4.6.2. Market Revenue and Volume Forecast, by Application

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Type

10.5.2. Market Revenue and Volume Forecast, by Application

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Type

10.5.3.2. Market Revenue and Volume Forecast, by Application

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Type

10.5.4.2. Market Revenue and Volume Forecast, by Application

Chapter 11. Company Profiles

11.1. Abbott

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Janssen Pharmaceuticals NV

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Sun Pharmaceutical Industries Ltd.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cipla Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Gilead Sciences, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Biogen

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Organon Group of Companies

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. AbbVie Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. AstraZeneca

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Salix Pharmaceuticals

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The major players operating in the gastric motility disorder drug market are Abbott, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd., Cipla Inc., Gilead Sciences, Inc., Biogen, Organon Group of Companies, AbbVie Inc., AstraZeneca, Salix Pharmaceuticals, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bayer AG and Others.

Answer : The driving factors of the gastric motility disorder drug market are the increase in the prevalence of GI disorders, rising pharmaceutical R&D spending, rising insurance coverage, ageing population patterns and rising healthcare costs.

Answer : North America region will lead the global gastric motility disorder drug market during the forecast period 2026 to 2035.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client